555 reports of this reaction
1.9% of all RALTEGRAVIR reports
#11 most reported adverse reaction
RENAL FAILURE is the #11 most commonly reported adverse reaction for RALTEGRAVIR, manufactured by Merck Sharp & Dohme LLC. There are 555 FDA adverse event reports linking RALTEGRAVIR to RENAL FAILURE. This represents approximately 1.9% of all 29,953 adverse event reports for this drug.
Patients taking RALTEGRAVIR who experience renal failure should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
RENAL FAILURE is a less commonly reported adverse event for RALTEGRAVIR, but still significant enough to appear in the safety profile.
In addition to renal failure, the following adverse reactions have been reported for RALTEGRAVIR:
The following drugs have also been linked to renal failure in FDA adverse event reports:
RENAL FAILURE has been reported as an adverse event in 555 FDA reports for RALTEGRAVIR. This does not prove causation, but indicates an association observed in post-market surveillance data.
RENAL FAILURE accounts for approximately 1.9% of all adverse event reports for RALTEGRAVIR, making it a notable side effect.
If you experience renal failure while taking RALTEGRAVIR, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.